1.820.3345.33 Contact@TravelTourWP.com


Sign Up

After creating an account, you'll be able to track your payment status, track the confirmation and you can also rate the tour after you finished the tour.
Confirm Password*
First Name*
Last Name*
* Creating an account means you're okay with our Terms of Service and Privacy Statement.

Already a member?


Prescribing Information


Sildenafil 50 mg / 100 mg Oral Strips


Sildenafil oral strip 50 mg

Each Oral Strip Contains Sildenafil Citrate equivalent to Sildenafil – 50 mg

Colour: Brilliant Blue

Sildenafil oral strip 100 mg

Each Oral Strip Contains Sildenafil Citrate equivalent to Sildenafil – 100 mg

Colour: Brilliant Blue


Blue colour oral strips

Chemical Name:

1-03-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-111-pyrazole(4,3- d)pyrimidine-5-y1)-4-ethoxyphenyl) sulfony1)-4-methylpiperazine


sildenafil oral strip 50mg,sildenafil oral strip 100mg,sildenafil mouth dissolving strips,ed drugs



The physiologic mechanism of erection of the penis involves a release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation.

NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but enhances the effect of nitric oxide (NO) by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil at recommended doses has no effect in the absence of sexual stimulation.


Erectile action: Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but enhances the effect of nitric oxide (NO) by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum.


Sildenafil is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (range 25-63%). Their pharmacokinetics is dose-proportional over the recommended dose range. It is eliminated predominantly by hepatic metabolism (mainly cytochrome P450 3A4) and is converted to an active metabolite with properties similar to the parent, sildenafil. Concomitant use of potent cytochrome P450 3A4 inhibitors (e.g erythromycin, ketoconazole, itraconazole) as well as the nonspecific CYP inhibitor, cimetidine, is associated with increased plasma levels of sildenafil (see dosage and administration). Both sildenafil and the metabolite have terminal half-lives of about 4 hours.

Absorption and Distribution:

Sildenafil is rapidly absorbed. Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When Sildenafil is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in T max of 60 minutes and a mean reduction in C max of 29%. The mean steady-state volume of Distribution (Vs) for sildenafil is 105 L, indicating Distribution into the tissues. Sildenafil and its major circulating N­desmethyl metabolite are both approximately 96% bound to plasma proteins. Protein binding is independent of total ED drug concentrations. Based upon measurements of sildenafil in semen of healthy volunteers 90 minutes after dosing, less than 0.001% of the administered dose may appear in the semen of patients.

Metabolism and Excretion:

Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-demethylation of sildenafil and is itself further metabolized. This metabolite has a PDE selectivity profile similar to sildenafil and an in vitro potency for PDE5, proximately of the parent drug. Plasma concentrations of the tablet are approximately 40% of those seen for sildenafil so that the metabolite accounts for about 20% of sildenafil’s pharmacologic effects. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose). Similar values for pharmacokinetic parameters were seen in normal volunteers and in the patient population, using a population pharmacokinetic approach.


V-Oral is indicated for: Treatment of erectile dysfunction patient may take ED drugs 30 minutes to 4 hours before sexual activity. Based on effectiveness and tolerance by the patient, may increase dose to maximum single dose of 100 mg or decrease dose to 50 mg. A maximum recommended dosing frequency is once daily.


Contraindicated in patients using organic nitrates and in those hypersensitive to drug or its components. Use cautiously in patients who have or can possibly had any MI, CVA, or life-threatening arrhythmias within the past 6 months; those with a history of cardiac failure, coronary artery disease, or uncontrolled high or low blood pressure; those with anatomic deformation of the penis; and those predisposed to priapism (sickle cell anemia, multiple myeloma, leukemia), retinitis pigmentosa, bleeding disorders, or active peptic ulcers.


The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following a complete medical assessment. Before prescribing V-oral strips, it is important to note the following:

Cardiovascular risk factors: Prior to initiating any erectile dysfunction treatment, physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. V-Oral has vasodilator properties, resulting in mild and transient decreases in blood pressure.

Priapism: Agents for erectile dysfunction treatment, including V-Oral, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma or leukemia).

Concomitant use with other treatments for erectile dysfunction: The safety and efficacy of combinations of V-Oral with other treatments for erectile dysfunction have not been studied. Therefore, the use of such combinations is not recommended.

Effects on vision: Cases of visual defects have been reported spontaneously in connection with the intake of V-Oral and other PDE5 inhibitors. Cases of non-arteritic anterior ischaemic optic neuropathy, a rare condition, have been reported spontaneously, and in an observational study in connection with the intake of sildenafil and other PDE5 inhibitors. Patients should be advised that in the event of any sudden visual defect, they should stop taking V-Oral and consult a physician immediately.

Concomitant use with ritonavir: Co-administration of V-Oral with ritonavir is not advised.

Concomitant use with alpha-blockers: Caution is advised when V-Oral Strips is administered to patients taking an alpha-blocker, as the co-administration may lead to symptomatic hypotension in a few susceptible individuals. This is most likely to occur within 4 hours post Voral dosing.

Effect on bleeding: Studies with human platelets indicate that V-Oral potentiates the anti aggregator effect of sodium nitroprusside in vitro. There is no safety information on the administration of sildenafil to patients with bleeding disorders or active peptic ulceration.

Women: Sildenafil is not indicated for use by women.

5 Interaction with other medicinal products and other forms of Interaction:

Care should be exercised by patients that are also taking protease inhibitors for the treatment of HIV. Protease inhibitors inhibit the metabolism of sildenafil, effectively multiplying the plasma levels of sildenafil, increasing the incidence and severity of side effects. It is recommended that patients using protease inhibitors limit their use of sildenafil to no more than one 25 mg dose every 48 hours. Other drugs that interfere with the metabolism of sildenafil include erythromycin and cimetidine, both of which can also lead to prolonged plasma half-life levels.


In the table below all medically important adverse reactions, which occurred in clinical trials at an incidence greater than placebo are listed by system organ class and frequency (very common (≥1/10), common (≥ 1/100 to <1/10), uncommon (≥1/1,000 to<1/100), rare ( ≥1/10,000 to, 1/1,000).

Sildenafil oral strips 50 mg


Sildenafil oral strips 100 mg




Headache 15% 12% 3%
Fulshing 8% 7% 1%
Dyspepsia 8% 9% 2%
Nasal Congestion 2% 3% 2%
Urinary Tract 1% 2% 2%
Abnormal Vision 1% 1% 0%
Diarrhea 1% 2% 1%
Dizziness 2% 2% 1%
Rash 2% 1% 1%


Abnormal Vision: Mild and to transient, predominantly vision, but also increased sensitivity to light or blurred vision. In these studies, only one part is discontinued due to abnormal vision. Other adverse reactions occurred at a rate of >21’Q, imt equally common on placebo: respiratory tract infection, back flu syndrome, and arthralgia. In fixed-dose studies, dyspepsia (17%) and abnormal vision (11%) were more common at 100 rag than at lower doses. At doses above the recommended dose range, adverse events were similar to those detailed above but generally were reported more frequently. The following events occurred in <2% of patients in control clinical trials; a causal rel’:,.  Sildenafil is uncertain. Repc..ted events include those plausible relations to drug use; omitted are minor events too imprecise to be meaningful:


In studies with healthy volunteers of a single dose, adverse events were similar to those seen at lower dose: incidence rates and severities were increased. In cases of overdose, standard supportive measures should be adopted as required. Penal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and it is not eliminated in the urine.


Always take this medicine exactly as your doctor or pharmacist has told you. The recommended starting dose is 50 mg and extend to . 100 mg. You should not take V-Oral more than once a day. Once should take V-Oral about 0.5 to 4 hours before you plan to have sex. You should keep the strip over the tongue as a whole and it dissolves within 60 sec without the aid of any water. If you feel the effect of Sildenafil is too strong or too weak, talk to your doctor or pharmacist. Sildenafil will only help you to get an erection if you are sexually stimulated. The amount of time Sildenafil takes to work varies from person to person, but it normally takes between half an hour and one hour. You should not take more Strips than your doctor tells you to. Contact your doctor if you take more Strips than you should. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.


Peel to open pouch. Take the strip out. Place the strip on the tongue.


Store at a temperature below 25’C protect from moisture, Do not use if the seal is open.

Shelf Life: 3 years from the date of Manufacturing.

Pack Size:

7 Sachets packed in one inner with the package insert.

Neutral Code No.: DRUGS/TS/01/2014

Marketed By:

ALL DAY EXIM, Vardhman market, Ram Vihar, Delhi-110092,

E-mail :- alldayexim@gmail.com


Visit Us On TwitterVisit Us On FacebookVisit Us On Google PlusVisit Us On PinterestVisit Us On Instagram